Beyond insulin treatment and diabetes management, a consumer-level CGM device (Lingo, Abbott, Abbott Park, IL, USA) has recently been released on the market for use by the general population to monitor glucose fluctuations in relation to lifestyle. This evidence concerns the gene INS and diabetes mellitus.